EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination CBD/THC in the management of chemotherapy-induced peripheral neuropathy: a randomized double blind controlled trial

Kombination aus CBD/THC zur Behandlung der chemotherapiebedingten peripheren Neuropathie: randomisierte, doppelblinde kontrollierte Studie

Marisa Weiss, Muath Giaddui, Stephanie Kjelstrom, Joseph Gary, Sara Jane Ward, Jessica Burrell, Katherine Diguilio, Gabrielle Bidas, Ebuwa Erebor, Sam Meske, Lisa Saeed, Sarah Windawi und 14 weitere

Frontiers in Oncology · 23.10.2025 · 15

DOI: 10.3389/fonc.2025.1590168 ↗

Auf einen Blick

In einer 12-wöchigen Studie mit Patient:innen mit CIPN zeigte CBD/THC im Primäranalyseschritt keinen Unterschied zu Placebo. In einer Sekundäranalyse verbesserte sich die sensorische Beeinträchtigung.

Fragestellung

Verbessert eine Kombination aus CBD und THC die Symptome einer chemotherapiebedingten peripheren Neuropathie bei Krebspatient:innen?

Methode

12-wöchige randomisierte, doppelblinde, placebokontrollierte Studie; danach 12-wöchige offene Beobachtungsstudie. Eingeschlossen waren Patient:innen mit nichtmetastasiertem Brust-, Kolorektal-, Endometrium- oder Ovarialkarzinom und CIPN Grad 2–3.

Ergebnisse

46 randomisiert, 43 beendeten 12 Wochen. Primäranalyse ohne Unterschiede zwischen CBD/THC und Placebo. Sekundäranalyse: QLQ-CIPN20 sensorische Beeinträchtigung verbessert (-10,4; 95 %-KI -20,5 bis -0,3; p=0,044).

Einschränkungen

Kleine Stichprobe; Ziel von 100 randomisierten Teilnehmenden verfehlt.

Schlussfolgerung der Autor:innen

Die Primäranalyse zeigte keinen Unterschied bei CIPN-Symptomen. Die Autor:innen sehen Hinweise, dass CBD/THC sensorische Beeinträchtigung und Berührung/Vibration verbessern könnte, dies müsse bestätigt werden.

Kernaussagen

  • Kein Unterschied in der Primäranalyse zwischen CBD/THC und Placebo
  • Sekundäranalyse: bessere sensorische Werte unter CBD/THC
  • Keine zwischen Gruppen unterschiedlichen Nebenwirkungen

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 23.10.2025. Verfasst von Marisa Weiss und 25 weiteren Autor:innen. Beteiligte Einrichtung: Lankenau Institute for Medical Research, Wynnewood, PA, United States. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Center for Complementary and Integrative Health.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chemotherapy-induced peripheral neuropathy (CIPN) can greatly impair function, leading to disability or truncated treatment in cancer patients. Previous animal studies show that cannabidiol (CBD) and delta-9- tetrahydrocannabinol (THC) can ameliorate CIPN. This study assessed the effect of combined CBD and THC on CIPN symptoms amongst cancer patients treated with taxane- or platinum-based agents. Materials and methods This 12-week randomized, double-blind, placebo-controlled trial included participants with nonmetastatic breast, colorectal, endometrial, or ovarian cancer experiencing grade 2–3 CIPN. The active group received CBD (125.3-135.9 mg) combined with THC (6.0-10.8 mg) in gelcaps. The Quality-of-Life Questionnaire-CIPN twenty-item scale (QLQ-CIPN20) sensory subscale was used as the primary outcome. Additional outcomes assessed pain, sleep, and function. Neurologic exams evaluated touch, pressure, and vibration sense. Following the randomized controlled trial, participants were invited to enroll in a 12-week open-label observational study.

Results

Of 230 participants identified, 124 met eligibility, 54 were enrolled, 46 were randomized, and 43 completed 12 weeks of treatment. This was lower than our goal of 100 randomized participants. The mean age was 60 +/- 9 years, 88% were female, 63% had breast cancer. All participants had completed chemotherapy. The primary analysis showed no differences in outcome measures between active and placebo groups, likely due to sample size. Although an increase in bilirubin (one participant in active group, and one in placebo) and alkaline phosphatase (one participant in active group) was seen, this did not exceed the exit criteria. A secondary analysis showed that the active group experienced greater improvement in the QLQ-CIPN20 measures of sensory impairment relative to placebo (-10.4 (95% -20.5, -0.3), p = 0.044). There was also improvement in light touch and vibration sensation of the feet on neurological exam that approached significance. There was no effect on other measures, including pain, and no between-group differences in side effects. The uncontrolled observational study showed similar results.

Discussion

The primary analysis showed no between-group difference in CIPN symptoms. The secondary analysis indicated that CBD with THC could improve sensory impairment and might increase touch and vibration sense, although these findings require confirmation in a future, more fully powered study. Nonetheless, our results show that combination CBD/THC can be safely delivered to participants with CIPN and suggest that these cannabinoids should be further investigated for this indication.

Schlagwörter

Stichwörter der Autor:innen

cancercannabidiol (CBD)cannabinoidschemotherapy-induced peripheral neuropathydelta-9-tetrahydrocannabinol (THC)sensory impairment

Autor:innen und Institutionen

  • Lankenau Institute for Medical Research, Wynnewood, PA, United States.
  • Lankenau Medical Center, Main Line Health, Wynnewood, PA, United States.
  • Breastcancer.org, Ardmore, PA, United States.
  • Center for Population Health Research, Main Line Health, Wynnewood, PA, United States.
  • College of Population Health, Thomas Jefferson University, Philadelphia, PA, United States.
  • Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, United States.

Förderung

  • National Center for Complementary and Integrative Health

Zitieren

APA

Weiss, M., Giaddui, M., Kjelstrom, S., Gary, J., Ward, S. J., Burrell, J., Diguilio, K., Bidas, G., Erebor, E., Meske, S., Saeed, L., Windawi, S., Aliano Ruiz, K., Ghaneie, A., Hibbs, J., Marks, J., Holtz, D., Ali, Z., Shevade, A., …, & Martinez, D. (2025). Combination CBD/THC in the management of chemotherapy-induced peripheral neuropathy: a randomized double blind controlled trial. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1590168

Vancouver

Weiss M, Giaddui M, Kjelstrom S, Gary J, Ward SJ, Burrell J, et al. Combination CBD/THC in the management of chemotherapy-induced peripheral neuropathy: a randomized double blind controlled trial. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1590168

BibTeX
@article{Weiss2025,
  author = {Weiss, Marisa and Giaddui, Muath and Kjelstrom, Stephanie and Gary, Joseph and Ward, Sara Jane and Burrell, Jessica and Diguilio, Katherine and Bidas, Gabrielle and Erebor, Ebuwa and Meske, Sam and Saeed, Lisa and Windawi, Sarah and Aliano Ruiz, Katherine and Ghaneie, Arezoo and Hibbs, Julianne and Marks, John and Holtz, David and Ali, Zonera and Shevade, Aarthi and Sabol, Jennifer and Ciocca, Robin and Zeger, Eric and Gilman, Paul and Larson, Sharon and Shimamoto, Shoichi and Martinez, Diana},
  title = {Combination CBD/THC in the management of chemotherapy-induced peripheral neuropathy: a randomized double blind controlled trial},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1590168}
}
Kostenlos starten →